MOB-015 Emerging Drug Insight

“MOB-015 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about MOB-015 for Onychomycosis in the seven major markets and China. A detailed picture of the MOB-015 for Onychomycosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, Japan and China for the study period 2019–2032 is provided in this report along with a detailed description of the MOB-015 for Onychomycosis.The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MOB-015 market forecast, analysis for Onychomycosis in the 7MM and China descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Onychomycosis.

Drug Summary

MOB-015 is a next-generation nail fungus treatment targeting over-the-counter (OTC) and prescription markets worldwide. The company’s patented formulation technology facilitates the delivery of high concentrations of a proven antifungal substance (terbinafine) into and through the nail. It has emollient and keratolytic properties that contribute to rapid, visible improvement.

MOB-015 is developed to meet unmet need and is patent protected by 2032 in most major markets, including the US, EU, Japan, and China.

Moberg Pharma has submitted a registration application in Europe through the decentralized process, with the Medical Products Agency in Sweden as the reference member state for the application. Moberg Pharma has submitted a full application, which offers the possibility of data exclusivity in Europe for up to 10 years following market approval.

The company’s main asset, MOB-015, is a novel topical treatment for onychomycosis. The data from Phase III clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements in place with commercial partners in Europe and Japan, among others, and the company's goal is to receive its first market approval and launch MOB-015 in 2023.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the MOB-015 description, mechanism of action, dosage and administration, research and development activities in Onychomycosis.
• Elaborated details on MOB-015 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MOB-015 research and development activity in Onychomycosis in detail across the United States, Europe, Japan and China.
• The report also covers the patents information with expiry timeline around MOB-015.
• The report contains forecasted sales of MOB-015 for Onychomycosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Onychomycosis.
• The report also features the SWOT analysis with analyst views for MOB-015 in Onychomycosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MOB-015 Analytical Perspective by DelveInsight

In-depth MOB-015 Market Assessment

This report provides a detailed market assessment of MOB-015 in Onychomycosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan and China. This segment of the report provides forecasted sales data from 2024 to 2032.

MOB-015 Clinical Assessment

The report provides the clinical trials information of MOB-015 in Onychomycosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Onychomycosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MOB-015 dominance.
• Other emerging products for Onychomycosis are expected to give tough market competition to MOB-015 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MOB-015 in Onychomycosis.
• Our in-depth analysis of the forecasted sales data from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MOB-015 in Onychomycosis.

Key Questions

• What is the product type, route of administration and mechanism of action of MOB-015?
• What is the clinical trial status of the study related to MOB-015 in Onychomycosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MOB-015 development?
• What are the key designations that have been granted to MOB-015 for Onychomycosis?
• What is the forecasted market scenario of MOB-015 for Onychomycosis?
• What are the forecasted sales of MOB-015 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), Japan and China?
• What are the other emerging products available in Onychomycosis and how are they giving competition to MOB-015 for Onychomycosis?
• Which are the late-stage emerging therapies under development for the treatment of Onychomycosis?